« Back

Sarah Noonberg

Dr. Noonberg has served as a member of our board of directors since December 2017. Dr. Noonberg has served as Prothena’s Chief Medical Officer since May 2017. Prior to joining Prothena, she served as Group Vice President and Head of Global Clinical Development at BioMarin Pharmaceuticals Inc., where she was responsible for development strategy and execution across a diverse clinical portfolio. From 2007 to 2015, Dr. Noonberg held several positions at Medivation, Inc. where, as Senior Vice President of Early Development and Vice President of Clinical Development, she led programs across all phases of development, including enzalutamide for the treatment chemotherapy-naïve metastatic prostate cancer. She also held several clinical positions between 2004 and 2007 at Chiron Corporation, where she led the clinical development of compounds in infectious disease and pulmonary indications. Dr. Noonberg earned her M.D. at the University of California, San Francisco and her Ph.D. in Bioengineering at the University of California, Berkeley. Dr. Noonberg is a board-certified internist and completed her residency at Johns Hopkins Hospital. Since 2002, she has been an active part-time hospitalist, working as an attending physician treating a broad range of inpatient and critical care patients.